Turning the tide or riding the waves? Impacts of antibiotic stewardship and infection control on MRSA strain dynamics in a Scottish region over 16 years: non-linear time series analysis

ABSTRACT

Objectives: To explore temporal associations between planned antibiotic stewardship and infection control interventions and the molecular epidemiology of methicillin-resistant Staphylococcus aureus (MRSA).

Design: Retrospective ecological study and time-series analysis integrating typing data from the Scottish MRSA reference laboratory.

Setting: Regional hospital and primary care in a Scottish Health Board.

Participants: General adult (N=1 051 993) or intensive care (18 235) admissions and primary care registrations (460 000 inhabitants) between January 1997 and December 2012.

Interventions: Hand-hygiene campaign; MRSA admission screening; antibiotic stewardship limiting use of macrolides and ‘4Cs’ (cephalosporins, coamoxiclav, clindamycin and fluoroquinolones).

Outcome measures: Prevalence density of MRSA clonal complexes CC22, CC30 and CC5/Other in hospital (isolates/1000 occupied bed days, OBDs) and community (isolates/10 000 inhabitant-days).

Results: 67% of all clinical MRSA isolates (10 707/15 947) were typed. Regional MRSA population structure was dominated by hospital epidemic strains CC30, CC22 and CC45. Following declines in overall MRSA prevalence density, CC5 and other strains of community origin became increasingly important. Reductions in use of ‘4Cs’ and macrolides anticipated declines in sublineages with higher levels of associated resistances. In multivariate time-series models (R²=0.63–0.94) introduction of the hand-hygiene campaign, reductions in mean length of stay (when >4 days) and bed occupancy (when >74 to 78%) predicted declines in CC22 and CC30, but not CC5/other strains. Lower importation pressures, expanded MRSA admission screening, and reductions in macrolide and third generation cephalosporin use (thresholds for association: 135–141, and 48–81 defined daily doses/1000 OBDs, respectively) were followed by declines in all clonal complexes. Strain-specific associations with fluoroquinolones and clindamycin reflected resistance phenotypes of clonal complexes.

Conclusions: Infection control measures and changes in population antibiotic use were important predictors of MRSA strain dynamics in our region. Strategies to control MRSA should consider thresholds for effects and strain-specific impacts.

INTRODUCTION

Staphylococcus aureus colonises around a third of humans, and is an important cause of infections in both hospital and community.1 Resistance to penicillinase-resistant penicillins was first recognised more than 50 years ago,2 and today methicillin-resistant S. aureus (MRSA) is among the most commonly identified resistant nosocomial infections worldwide.3 Resistance to β-lactam antibiotics is conferred by acquisition of a mobile genetic element: the Staphylococcal cassette chromosome (SCCmec).4 This section of DNA...
contains the \textit{mecA} gene, encoding for a modified penicillin binding protein; cassette chromosome recombinase genes, allowing for its excision and horizontal transfer; and variable elements encoding additional antibiotic resistances.\textsuperscript{5-6} Rapid adaptation to selective pressures within a clonal genomic background facilitates clonal expansion and diversification, and this biodiversity allows MRSA to occupy a range of ecological niches.\textsuperscript{7} Hospital-associated (HA-) strains typically contain \textit{SCCmec} types I–III, encoding resistance to multiple antibiotics but also associated with slower growth and reduced toxin expression.\textsuperscript{5} This fitness burden means HA-MRSA strains are typically limited to contexts of high-antibiotic pressure and high density of vulnerable hosts. Community-associated (CA-) MRSA strains are characterised by \textit{SCCmec} types IV–XI, carrying variable resistance to antibiotics and small fitness burdens.\textsuperscript{5} These strains have a fitness advantage where selective pressures of antibiotic use fall below critical levels, and can infect healthy populations. Interactions of strains in hospital and community are increasingly recognised.\textsuperscript{5-9} The hospital epidemic strain EMRSA-15 is \textit{SCCmec} IV, retaining some features consistent with its origin in the community.

The complex and evolving MRSA population structure creates challenges in the design and evaluation of control measures.\textsuperscript{11} In the UK, national initiatives of infection control and antibiotic stewardship have been linked to a declining MRSA epidemic.\textsuperscript{12-14} However, intervention effects may be strain-specific: the offset of fitness advantage and antibiotic resistance suggests that modifying ecological pressures could lead to clonal replacement.\textsuperscript{10} \textsuperscript{11} \textsuperscript{15} Wyllie \textit{et al}.\textsuperscript{16} \textsuperscript{17} have even suggested that declines in MRSA are attributable to spontaneous evolution within the MRSA population rather than impacts of infection control, and that health systems will continue to ride `waves of trouble’.

The ability to identify MRSA strains by molecular typing provides a tool for mapping their evolution and spread, and may inform more effective control strategies.\textsuperscript{18} European studies have linked strain dominance to clinical context and antibiotic use,\textsuperscript{15} \textsuperscript{19} \textsuperscript{20} with a particular focus on fluoroquinolones.\textsuperscript{10} \textsuperscript{21} \textsuperscript{22} \textsuperscript{23} Advanced time-series analysis is well suited to investigating evolution in MRSA population structure, since it can distinguish the intrinsic progression of naturally occurring time series from external influences of changes in ecological pressures.\textsuperscript{24} While such analyses have explored associations between infection control measures and total MRSA rates,\textsuperscript{25} \textsuperscript{26} \textsuperscript{27} \textsuperscript{28} \textsuperscript{29} \textsuperscript{30} \textsuperscript{31} we are not aware of any previous application to strain dynamics. Mathematical models have suggested critical thresholds in the impacts of ecological pressures, such as total antibiotic use, on resistance,\textsuperscript{30} \textsuperscript{31} but to date empirical studies have only defined linear associations.

In this intervention study we used non-linear time-series analysis to investigate the extent to which national antibiotic stewardship and infection control strategies have determined the molecular epidemiology of MRSA across a Scottish health board between January 1997 and December 2012.

\textbf{METHODS}

\textbf{Study design}

This retrospective observational study explored temporal associations between clinical burdens from MRSA clonal complexes and recent ecological exposures. Strain distribution and exposures were measured at monthly intervals over 16 years. This time frame reflected the availability of routine typing data and covered a period of emergence, stabilisation and decline in MRSA. It also allowed evaluation of the impacts of national infection control and antibiotic stewardship strategies, prompted by detection of high rates of nosocomial infection in mandatory surveillance. Analysis controlled for natural progression within time series of MRSA strain, strain competition and interactions between different clinical populations.

\textbf{Setting and population}

\textit{NHS Grampian} is a large health board, serving 11% of Scotland’s population. We investigated strain dynamics in three care settings: primary care (community), and general surgical/medical wards (hospital) or intensive care units (ICU) of the 1000-bed regional referral hospital—Aberdeen Royal Infirmary (ARI). Less than 5% of admissions were transferred from other hospitals or regions. See table 1 for further details of participants.

\textbf{Outcomes and exposures}

The primary outcomes for the study were hospital-associated and community-associated prevalence densities of infections (de-duplicate clinical isolates) involving major clonal complexes grouped as CC22; CC30; and CC5/other strains. Data on prior healthcare exposures were not available so CA-MRSA included infections described elsewhere as healthcare associated.

We considered a number of ecological exposures previously associated with MRSA burdens. Monthly population antibiotic use was measured in defined daily doses (DDDs)/1000 occupied bed days (OBDs) in hospital, or DDDs/1000 inhabitant-days (IDs) in the community, and summarised according to the WHO Anatomical Therapeutic Chemical (WHO/ATC) classification.\textsuperscript{35} Other covariates included: MRSA admission screening intensity (admissions screened/1000 OBDs); total and strain-specific importation pressures (admissions colonised or previous MRSA/1000 OBDs); mean length of stay (days) and bed-occupancy (%) in hospital populations. Consistent data on alcohol gel consumption and preintervention adherence with hand hygiene or environmental cleaning standards were not available. We therefore introduced instrumental variables coding for changes in level (0 prior, 1 during intervention) and trend (autoregression×intervention) in strain prevalence densities associated with start of intervention.
Data collection

Typing and antibiotic resistance phenotype data were derived from the Scottish MRSA Reference Laboratory (SMRSARL) for 10,707 MRSA clinical isolates and 4,273 MRSA admission screening specimens from non-duplicate cases. Total antibiotic consumption in primary care was derived from the Prescribing Information System for Scotland (PRISMS). Remaining data was retrieved from regional health intelligence, pharmacy, microbiology and infection control departments. Any individual or specimen level data were pseudonymised by removal of identifiable personal information and replacement of unique personal or specimen numbers with matched study codes.

Laboratory methods

All *S. aureus* isolates were identified by agglutination, mainly with the Prolex– Blue Staph Latex Kit (Pro-Lab). Antibiograms were determined using Clinical and Laboratory Standards Institute agar disk diffusion methods and, from 2008, by a Vitek instrument, using custom made *Staphylococcus* sensitivity cards (Biomerieux). EUCAST interpretative criteria were used from January 2012. MRSA screening swabs were cultured...
on MRSA selective medium, with use of chromogenic agar (Brilliance—Oxoid, UK) from 2006. Further details of methods utilised in the study period are available from previous publications. All first patient clinical and screening isolates per year were sent to the reference lab until March 2011, after which only isolates from screening, blood cultures, outbreak investigations, or with unusual phenotypes were referred. Epidemiological typing of MRSA isolates into clonal complex was based on a combination of genotypic and phenotypic characteristics, matching >90% to known strains. Isolates were typed by the methods in use at the reference laboratory at the time of receipt. These varied during this study but always involved at least two independent methods. All isolates had their antibiotic resistance profile and biotype determined and at least one of phage typing, pulsed-field gel electrophoresis (PFGE), PCR-ribotyping or spa typing was not one commonly associated in Scotland with the strain. High prevalence densities of CC22 were characterised by resistance to erythromycin, ciprofloxacin and clindamycin and associated resistances (% isolates) in each MRSA strain.

To investigate the dissemination of clonal complexes through the regional healthcare network we considered temporal associations between strain prevalence density in ICU, hospital and community and among those colonised with MRSA at admission. Granger causality tests were used to identify the direction of possible relationships (at lags 1–3 months). Long-run associations between time-series were defined by the Johansen cointegration test, and used to inform a Vector Error Correction model (lags 1–3 months) incorporating cointegration equations. Path diagrams were generated based on significant associations in these models, with connecting arrows proportional to the percentage of total variation in prevalence density explained by variation in other populations.

Finally, we used non-linear time-series analysis to explore significant predictors of strain prevalence density in hospital (full details are provided in online supplementary file 1). Potentially significant non-linear associations were identified from visual inspection of the output from Generalised Additive Models (GAM). Candidate variables were entered into Multivariate Adaptive Regression Spline (MARS) models defining associations as a series of linear segments across ranges of the independent variables separated by thresholds (knots). Analyses were performed using SPSS V21.0 (IBM), Eviews V8.0 (IHS, California, USA) and SCA V8.1 (Scientific Computing Associates Corp, Illinois, USA).

**RESULTS**

**Trends in MRSA clonal complexes**

Information on epidemiological typing was available for 60% (n=4597/7727) of clinical isolates in the hospital population, 74% (5651/7647) of isolates in the community and 80% (459/573) in the ICU (figure 1A). Applying strain distributions (figure 1B) to the total MRSA prevalence densities in each population provided estimates of strain-specific prevalence densities (figure 1C).

A consistent secular trend in strain distribution was seen across all three populations. Between 1997 and 2003 CC30 (mostly UK-EMRSA-16) was the dominant strain. High prevalence densities of CC30 were seen in ICU before introduction of MRSA admission screening in this unit (May 2001), with little presence in the community. Between 2004 and 2008 the dominant strains were CC22 (UK-EMRSA-15) and, to a lesser extent, CC45 (limited to our region in Scotland), with large clinical burdens in all settings. Finally, from 2008 there was greater strain diversity, with CC5, CC8, CC1 and other clonal complexes of increasing importance. These strains explained 30% of HA-MRSA and 50% of CA-MRSA by 2012.

**Trends in antibiotic resistance phenotypes and sublineages**

Excluding resistance phenotypes represented by ≤5 isolates over the study period, MRSA isolates could be explained by 37 antibiograms (figure 2). Ninety-four per cent of CC30 and 90% of CC45 isolates were resistant to erythromycin, ciprofloxacin and clindamycin, and 78% of CC22 were characterised by resistance to erythromycin and ciprofloxacin. By contrast 92% of CC5 were susceptible to all three agents. Multidrug resistance (≥3 antibiotic classes) was present in 88% (95% CI, 87% to 90%) of isolates before the third quarter of 2008, declining sharply thereafter to 60% (57% to 63%). Multidrug resistance in CC22, increased from 6% when CC30 was dominant to 57% when CC22 was dominant (2004–2008), falling to 25% during antibiotic stewardship; Kruskal-Wallis test, p=0.002. The most commonly acquired resistances in CC22 included trimethoprim (4% increasing to 66%; p<0.001), tetracycline (1.4% to 10.7%; p<0.001),
clindamycin (1.3% to 3.9%); p<0.001 for all comparisons. Concurrent increases in trimethoprim resistance were observed in CC30 (0.7% to 7.3%; p<0.001), but not CC5/other strains (10.5% to 4.8%; p=0.058).

Changes in antibiotic resistance phenotypes of prevalent strains were predicted by trends in antibiotic consumption. During antibiotic stewardship resistance to erythromycin, ciprofloxacin and clindamycin declined in all strains (table 2 and figure 3).

Changes in antibiotic resistance phenotypes within strains were partially explained by shifts in the distribution of sublineages (figure 4). Before antibiotic stewardship, hospital epidemic strains were dominated by sublineages with high rates of resistance to ciprofloxacin, erythromycin and clindamycin, including ST22-MRSA-IV (E15), ST36-MRSA-II (E16) and ST45-MRSA-II. During antibiotic stewardship higher proportions of isolates within these strains were from alternative sublineages, characterised by much lower rates of resistance to these three antibiotics. Conversely, within strains dominated by sublineages with low rates of resistance (including CC5 and CC8), alternative and more resistant sublineages, such as SM119, Tayside E3 and CC5-II, declined during antibiotic stewardship. One exception was the increasing importance within CC8 of Panton-Valentine Leukocidin (PVL) positive isolates, resembling USA300.6

**Interactions of MRSA population structure in different populations**

Typing was available for 33% (4273/13 048) of non-duplicate MRSA admission screening isolates. Applying the strain distribution from this typing to the total MRSA positive admission swabs per month provided time-series for strain-specific importation pressures for general hospital and ICU environments. Trends in strain-specific importation pressures coincided with the strain dynamics seen among clinical isolates.

Granger causality tests and Vector Error Correction (VEC) models confirmed significant temporal associations between prevalence density of strains in ICU, hospital and community populations and strain-specific importations pressures (figure 5). Importation pressures followed trends in related hospital prevalence densities, with less consistent and sizeable associations with

Figure 1 (A) Epidemiological typing of clinical MRSA isolates, and distribution of clonal complexes† as (B) cumulative per cent typed isolates or (C) prevalence density by population. †Other clonal complexes included CC7, CC15, CC59, CC88, CC93 and C239; †Cases/1000 OBDs (hospital) or Cases/10 000 IDs (community); §Estimated by applying % strain distribution (B) to population MRSA prevalence densities (A).
community or ICU trends. Community prevalence densities of CC22, CC30 and CC45 were strongly determined by prior rates in hospital and ICU. By contrast, hospital epidemiology of CC5/other was anticipated by rates in the community.

**Multivariate time series analyses**

MARS models explained 91%, 94% and 58% of variation in prevalence densities of CC22, CC30 and CC5/other strains, respectively (table 3).

Prevalence densities of CC22 and CC30 were inversely related suggesting competition for the same ecological niche. Bed occupancies above 74 to 78% and length-of-stay over 4 days, were associated with higher rates of CC22 and CC30 over the next 1 to 3 months (lags 1–3) (figure 6). The negative coefficient for the interaction term hand hygiene×AR (1) suggests the hand-hygiene campaign exerted a downward pressure on CC22 strongest in months of high prevalence density (where values of AR (1) were high). No association was noted with CC30 prevalence density which was already low at initiation of the campaign. In contrast, rates of CC5/other strains increased when length-of-stay was <4 days and were not related to hand hygiene or bed occupancy.

**Figure 2**  Heat map of antibiotic resistance phenotypes including total number in study period, percentage of isolates in each strain and percentage of all isolates per quarter of year.
Table 2  Temporal associations between hospital use of macrolides, fluoroquinolones and clindamycin and related antibiotic resistances within strains

| Antibiotic and strain | ARIMA model* (p,d,q) (P,D,Q) | Model R^2 | Lag | Coefficient (95% CI)† | T ratio | p Value |
|-----------------------|-----------------------------|-----------|-----|-----------------------|---------|---------|
| **Macrolide use, DDDs/1000 OBDs** | | | | | | |
|  CC22, % erythromycin resistance | (1,0,1) (1,0,0) | 0.291 | 0 | 0.088 (0.012 to 0.164) | 2.25 | 0.026 |
|  CC30, % erythromycin resistance | (2,0,2) (0,0,0) | 0.432 | 5 | 0.098 (0.006 to 0.190) | 2.08 | 0.039 |
|  CC5 and other, % erythromycin resistance | (1,0,0) (0,0,0) | 0.109 | 0 | 0.110 (0.090 to 0.130) | 11.51 | <0.001 |
| **Fluoroquinolone use, DDDs/1000 OBDs** | | | | | | |
|  CC22, % ciprofloxacin resistance | (2,0,2) (1,0,0) | 0.451 | 0 | 0.062 (0.027 to 0.097) | 3.36 | 0.001 |
|  CC30, % ciprofloxacin resistance | (2,0,2) (1,0,0) | 0.331 | 0 | 0.128 (0.048 to 0.209) | 3.14 | 0.002 |
|  CC5 and other, % ciprofloxacin resistance | (1,0,2) (0,0,0) | 0.074 | 0 | 0.108 (0.076 to 0.140) | 6.58 | <0.001 |
| **Clindamycin use, DDDs/1000 OBDs** | | | | | | |
|  CC22, % clindamycin resistance | (1,0,1) (0,0,0) | 0.298 | 0 | 0.173 (0.137 to 0.208) | 9.76 | <0.001 |
|  CC30, % clindamycin resistance | (2,0,1) (0,0,0) | 0.691 | 0 | 0.455 (0.067 to 0.843) | 2.30 | 0.023 |
|  CC5 and other, % clindamycin resistance | (2,0,1) (0,0,0) | 0.176 | 0 | 0.334 (0.175 to 0.493) | 4.11 | <0.001 |

*Autoregressive Integrated Moving Average models, in which: p=order (number) of non-seasonal autoregressive terms representing impact of previous values in time-series, d=order of differencing to achieve stationary time-series; q=order of non-seasonal moving average terms representing response to previous disturbances (residual error) in time-series; and P, D, Q reflect orders of seasonal (lag 12) autoregressive, differencing and moving average terms.

†Change in % resistance associated with a +1 DDD/1000 OBDs increase in antibiotic use.

DDD, defined daily doses; OBD, occupied bed days.

Figure 3  Percentage of isolates within strains resistant to erythromycin, ciprofloxacin or clindamycin and consumption of related antibiotics from univariate ARIMA time-series models (3 m moving averages).
Importation pressure was important in determining nosocomial rates of CC22 and CC30 at almost all levels, whereas association with CC5/other strains was mostly at high importation pressures (>6.24 MRSA+ admissions/1000 OBDs). Increased intensity of MRSA admission screening was followed by declines in prevalence density of CC30, CC22 and CC5/other beyond thresholds of 5, 70 and 110 admissions screened per 1000 OBDs, respectively. The difference in threshold reflected the influence of earlier ICU screening on CC30, when overall inpatient screening levels were low.

Consistent non-linear associations were seen between inpatient macrolide or third generation cephalosporin use and prevalence density of all strains (figure 6). Macrolide consumption was positively associated with rates of CC30, CC22 and CC5, above a total use threshold of 125–141 DDDs/1000 OBDs. A ‘ceiling’ effect was noted for all associations with third generation cephalosporin use, with reductions in consumption below 71–81 DDDs/1000 OBDs associated with lower prevalence densities, but no relationship seen above this threshold. A threshold effect was also observed with coamoxiclav use above 235–241 DDDs/1000 OBDs being followed by similar increases in CC22 and CC5/other prevalence density, but a positive association with CC30 was only seen at lower levels of consumption (up to 160 DDDs/1000 OBDs).

Other strain-specific associations reflected the resistance phenotype of the strain. Clindamycin consumption above 25 DDDs/1000 OBDs was positively associated with rates of CC30, but was not significantly related to CC22 or CC5/other strains at any level of use. Increases in CC30 prevalence density were seen at levels of fluoroquinolone use up to 68 DDDs/1000 OBDs (lag 4). Consumption above this level was inversely associated with CC30 but positively associated with CC22, suggesting selective advantage of CC22 under higher antibiotic pressure.

Where antibiotic consumption was positively associated with strain prevalence density, the median (range) percentage isolates within strains with related resistances was 98.1% (40–100%), compared to 3.7% (3.5–32%) where no association was identified (Mann-Whitney U test, p=0.004). Consumption of other antibiotics in hospital or community were not significantly related to strain dynamics.

### DISCUSSION

This 16-year retrospective study represents the first ever application of non-linear time-series analysis to investigate ecological determinants of MRSA strain dynamics. Following recent declines in hospital-associated epidemic strains such as CC22 and CC30, clonal complexes arising from the community, including CC5, became

---

**Figure 4** Heat map describing relative frequency (percentage of total isolates in strain per quarter) of sublineages of the five most prevalent clonal complexes.
increasingly important in the region. Large shifts in strain distribution were underpinned by more subtle changes in sublineages and antibiotic phenotypes associated with changes in selective pressure from antibiotic use. Even after accounting for interactions between clinical populations, and natural progression within time series, we demonstrated that changes in infection control and antibiotic use were important predictors of this evolving MRSA population structure. Improved hand hygiene, and reductions in bed occupancy or length of stay, were followed by declining inpatient burdens from HA epidemic strains but had little or opposite effects on community strains. The HA prevalence density of all clonal complexes declined with increasing intensity of admission screening, but thresholds for association were strain specific. Responses to consumption of antibiotics reflected the resistance phenotype of the strain and were subject to total use thresholds.

This study had several limitations. An observational and ecological design meant that associations may not be causal, may be explained by unidentified confounding variables, and may not reflect variation in molecular epidemiology due to individual-level exposures. However, although retrospective in nature, use of routinely collected data from electronic databases and standardised microbiological and clinical definitions minimised risks of information bias. Change in criteria for sending isolates for typing (March 2011) was not likely to introduce bias since: major changes in antibiotic use and infection control occurred before this time, and covariates and direction of associations in baseline models for months before were unchanged; time series for strain distribution derived from isolate types sent throughout the study period were strongly correlated with time series derived from wider range of isolates typed before the change in criteria (R² for 5-month moving averages=0.85–0.96). Use of a long-time series (N=192) and restriction of candidate explanatory variables through two-step GAM and MARS procedures helped to reduce the potential for spurious (chance) associations. Nevertheless measures of uncertainty around associations may be underestimated where data are used for model estimation and hypothesis testing. Further applications of our approach to other, similar, data sets is required to validate parameters reported here. Between 6% and 42% of variation in strain prevalence densities was not explained by multivariate models, suggesting unidentified determinants. We were unable to obtain consistent data on: staffing levels, transfer rates, isolation and decolonisation performance, and compliance with hand hygiene and environmental cleaning before initiation of national strategies. External validity was strengthened by exploring strain dynamics in a geographically-defined population covered by a universal health system, and in various levels of care. However, our findings also highlight the importance of healthcare environments and local ecological exposures in shaping strain dynamics, which may limit generalisability of specific associations.

Figure 5  Flow charts of temporal associations between prevalence density of MRSA strains in different clinical populations, as derived from Vector Error Correction (VEC) models. Boxes represent patient populations, arrows the direction of temporal association and numbers (months) the delay in associated changes. Arrow width is proportional to the percentage of total variation in response time-series (population prevalence density) explained by input time-series.

Lawes T, et al. BMJ Open 2015;5:e006596. doi:10.1136/bmjopen-2014-006596
### Table 3  Summary of time series multivariate adaptive regression splines models

| Explanatory variables (order of terms) | Lag (months) | Threshold† | Relation to threshold | Change in prevalence density (95% CI) | T-ratio | p Value   |
|--------------------------------------|--------------|------------|------------------------|--------------------------------------|---------|-----------|
| (a) CC22 ($R^2=0.912$)              |              |            |                        |                                      |         |           |
| AR (1)                               | 1            | 1.06       | Above                  | +0.474 (0.271 to 0.677)              | 4.57    | <0.001    |
| AR (2)                               | 1            | 2.18       | Above                  | −0.530 (−0.941 to −0.119)            | −2.52   | 0.023     |
| CC30 prevalence density, cases/1000 OBDs | 0            | 0.363      | Above                  | −0.337 (−0.483 to −0.231)            | −6.26   | <0.001    |
| Mean bed-occupancy, %                | 3            | 78.4       | Above                  | +0.022 (0.006 to 0.038)              | 2.66    | 0.017     |
| Mean length of stay, days            | 2            | 4.06       | Above                  | +0.694 (0.178 to 1.210)              | 2.63    | 0.018     |
| Hand-hygiene campaign × AR (1), trend effect | 6            | 0.26       | Above                  | −0.143 (−0.231 to −0.055)            | −3.16   | 0.006     |
| Admissions screened for MRSA/1000 OBDs (1) | 1            | 4.24       | Above                  | +0.138 (0.088 to 0.188)              | 5.38    | <0.001    |
| Admissions screened for MRSA/1000 OBDs (2) | 1            | 7.87       | Above                  | −0.137 (−0.188 to −0.086)            | −5.26   | <0.001    |
| Admissions screened for MRSA/1000 OBDs (3) | 1            | 69.7       | Above                  | −0.007 (−0.012 to −0.002)            | −2.42   | 0.028     |
| MRSA+ at admission/1000 OBDs         | 0            | 0.145      | Above                  | +0.178 (0.125 to 0.231)              | 6.53    | <0.001    |
| Fluoroquinolone use, DDDs/1000 OBDs (1) | 2            | 78.6       | Above                  | +0.033 (0.009 to 0.057)              | 2.69    | 0.016     |
| Fluoroquinolone use, DDDs/1000 OBDs (2) | 2            | 72.8       | Above                  | −0.032 (−0.055 to −0.009)            | −2.62   | 0.019     |
| Macrolide use, DDDs/1000 OBDs        | 1            | 135        | Above                  | +0.009 (0.002 to 0.015)              | 2.62    | 0.019     |
| Coamoxiclav use, DDDs/1000 OBDs      | 2            | 235        | Above                  | +0.010 (0.004 to 0.016)              | 3.10    | 0.007     |
| Third Gen. Cephalosporin use, DDDs/1000 OBDs | 5            | 81.0       | Below                  | −0.007 (−0.010 to −0.004)            | −4.22   | <0.001    |
| (b) CC30 ($R^2=0.940$)               |              |            |                        |                                      |         |           |
| AR (1)                               | 1            | 1.189      | Above                  | +6.40 (4.48 to 8.311)                | 6.54    | <0.001    |
| AR (2)                               | 1            | 1.273      | Above                  | −6.62 (−8.85 to −4.40)               | −5.84   | <0.001    |
| AR (3)                               | 1            | 1.773      | Above                  | +0.794 (0.240 to 1.349)              | 2.80    | 0.010     |
| CC22 prevalence density, cases/1000 OBDs (1) | 0            | 0.157      | Below                  | +4.34 (2.99 to 5.71)                | 6.28    | <0.001    |
| CC22 prevalence density, cases/1000 OBDs (2) | 0            | 0.157      | Below                  | −0.207 (−0.288 to −0.126)            | −5.01   | <0.001    |
| Mean bed-occupancy, %                | 1            | 73.7       | Above                  | +0.021 (0.009 to 0.033)              | 3.50    | 0.002     |
| Mean length of stay, days            | 1            | 3.85       | Above                  | +0.531 (0.274 to 0.787)              | 4.05    | <0.001    |
| Admissions screened for MRSA/1000 OBDs (1) | 1            | 5.11       | Above                  | −0.007 (−0.008 to −0.005)            | −8.92   | <0.001    |
| MRSA+ at admission/1000 OBDs (1)     | 0            | 0.498      | Below                  | −2.442 (−3.382 to −1.501)            | −2.91   | 0.008     |
| MRSA+ at admission/1000 OBDs (2)     | 0            | 0.498      | Below                  | −2.492 (−4.596 to −1.247)            | −2.91   | 0.008     |
| MRSA+ at admission/1000 OBDs (3)     | 0            | 0.623      | Above                  | +2.86 (1.15 to 4.56)                | 3.27    | 0.003     |
| MRSA+ at admission/1000 OBDs (4)     | 0            | 3.038      | Above                  | −0.361 (−0.464 to −0.258)           | −6.86   | <0.001    |
| Fluoroquinolone use, DDDs/1000 OBDs (1) | 4            | 49.4       | Below                  | −0.049 (−0.071 to −0.027)            | −4.38   | <0.001    |
| Fluoroquinolone use, DDDs/1000 OBDs (2) | 4            | 49.4       | Above                  | +0.018 (0.017 to 0.019)              | 3.92    | <0.001    |
| Fluoroquinolone use, DDDs/1000 OBDs (3) | 4            | 67.3       | Above                  | −0.021 (−0.031 to −0.011)            | −4.16   | <0.001    |
| Macrolide use, DDDs/1000 OBDs        | 1            | 141        | Above                  | +0.022 (0.016 to 0.028)              | 7.05    | <0.001    |
| Coamoxiclav use, DDDs/1000 OBDs      | 5            | 160        | Below                  | −0.005 (−0.008 to −0.002)            | −3.35   | 0.003     |
| Coamoxiclav use, DDDs/1000 OBDs      | 5            | 160        | Above                  | −0.003 (−0.005 to −0.001)            | −3.82   | <0.001    |
| Third gen. Cephalosporin use, DDDs/1000 OBDs | 5            | 71.9       | Below                  | −0.008 (−0.013 to −0.003)            | −3.74   | 0.001     |
| (c) CC5/Other strains ($R^2=0.583$)  |              |            |                        |                                      |         |           |
| AR (1)                               | 2            | 0.166      | Below                  | −0.314 (−0.575 to −0.05)             | −2.35   | 0.018     |
| AR (2)                               | 2            | 0.166      | Above                  | −0.22 (−0.370 to −0.070)             | −2.87   | 0.007     |
| AR (3)                               | 1            | 0.273      | Above                  | −0.457 (−0.657 to −0.257)            | −4.47   | <0.001    |
| Mean length of stay, days            | 1            | 3.98       | Below                  | +0.177 (0.097 to 0.257)              | 4.33    | <0.001    |

Continued
Previous evidence on associations between infection control measures or antibiotic use and MRSA strain-dynamics has largely been from in vitro or animal experiments, and mathematical models. While such studies have demonstrated important concepts of strain competition and strain-specific impacts of manipulating selective pressures, examining the evolution of MRSA in real-life contexts provides greater ecological and population validity. Wyllie et al. have highlighted the importance of considering internal strain-dynamics when evaluating the contribution of national infection control strategies to recent declines in MRSA within the UK. In a large observational study, these authors explored the evolution of MRSA and two epidemic strains (CC30 and CC22) in Oxfordshire hospitals alongside infection control strategies. They concluded that recent falls in MRSA rates were more likely attributable to spontaneous strain dynamics than interventions since: declines were seen before intensification of infection control; and decline in CC30 was much steeper than that in CC22. Elsewhere, in a 10-year study of an MRSA population in a London hospital, Knight et al. noted a similar shift in dominant strain from CC30 to CC22, and attributed it to fitness advantage in CC22 after acquisition of additional resistances. This evolution was independent of ecological pressures, but fluoroquinolone resistance was a key feature of successful hospital strains and overall MRSA declined after restriction of these antibiotics. These investigations made limited attempts to model impacts of interventions and changing antibiotic use, adjust for expected progression of time series, or consider population interactions. In overcoming these methodological weaknesses, our study helps reconcile conflicting evidence.

First, results of multivariate models suggest that even those infection control measures expected to have general effects can have strain-specific impacts due to differences in the temporal and spatial distribution of clonal complexes. Threshold effects of hand hygiene have been identified previously. Our findings also suggest that impacts of a national initiative to improve hand hygiene were dependent on background prevalence densities of CC22 and CC30 during the campaign. Greater impact during period of high prevalence density is consistent with the role of hand hygiene in reducing transmission, and of diminishing returns at lower prevalence density. Several time-series analyses have demonstrated the importance of bed occupancy in determining rates of MRSA, with both guidelines and research suggesting safety thresholds between 82 and 90%. We found highly consistent associations between bed occupancy and rates of CC22 and CC30 above thresholds of 74–78%; much lower than average bed occupancies of 82–88% across the UK. The association with bed occupancy was not explained by variation in mean inpatient age and seasonality, but may reflect changes in case-mix during winter rather than increased transmission. Congruent with hospital burdens
from CC5/other strains being driven by importation from the community, no associations were seen with hand hygiene or bed occupancy. Similarly while lower average length of stay anticipated declines in CC22 and CC30, it was associated with increases in hospital burdens from CC5/other strains. Given that antibiotic-resistant infections lead to longer length of stay a complex bidirectional relationship is likely. We noted the threshold of hospital-wide MRSA admission screening at which declines were seen varied considerably between strains, probably reflecting the roll-out among different clinical populations, and background rates of strains. Population interaction models suggested that ICU was a key environmental niche for CC30, consistent with a highly drug resistance phenotype. Early introduction of admission screening in this unit (May 2001) resulted in an abrupt and permanent decline in total MRSA rates, which this study suggests was attributable to control of CC30. Responsiveness may also reflect much more frequent carriage of qacA, encoding for chlorhexidine resistance, in CC22 compared to CC30. However, we have not identified increasing chlorhexidine resistance in the ICU. Declines in CC22 and CC5/other strains were limited to months when hospital-wide screening exceeded 70 and 110 admissions screens/1000 OBDs: a level only seen during expansion to high-dependence unit/surgical and universal admission screening, respectively. On the basis of cost-effectiveness, risk-factor-based (targeted) screening is advocated in Scotland. However, since community strains can appear in patients without traditional risk-factors for MRSA, this approach may be insufficient to prevent invasion into hospitals.

We further demonstrated the importance of selective pressures from population antibiotic use in determining the molecular epidemiology of MRSA. Alongside non-linear associations strongly related to the typical resistance profiles of strains, declining use of ‘4C’ and macrolide antibiotics coincided with changes in antibiotic resistance phenotypes and shift towards more susceptible sublineages within all clonal complexes. Total antibiotic use thresholds may represent ‘tipping points’ at which ability to adapt to different selective pressure determines strain success within environmental niches. The rapidity of change within strains during hospital antibiotic stewardship is in keeping with mathematical models demonstrating declines in resistance within weeks to months, even in the absence of high fitness costs. Studies in France have described secular trends towards strains and resistance phenotypes with susceptibility to macrolides and gentamicin despite a lack of change in antibiotic consumption. However, use of macrolides in these areas was around 40 DDDs/1000 OBDs, and well below the thresholds for association...
with strain prevalence in our study. The studies also highlighted the selective advantage of strains carrying SCC type IV, associated with high genetic plasticity mediated by the frequent transfer of mobile genetic elements. Consistent with Knight et al, we noted that dominance of CC22-IV in hospital coincided with acquisition of multiple antibiotic resistances. We have previously noted increasing trimethoprim resistance in major epidemic strains associated with regional use in MRSA throat decolonisation. Our finding that CC22 outcompeted CC30 at higher intensity of fluoroquinolone (FQ) use is congruent with lower fitness costs of FQ resistance in CC22, and its critical role in the dissemination of CC22 through the UK health system.

Our findings suggest that implementation and evaluation of interventions to control MRSA can be improved by consideration of non-linear and strain-specific impacts. Recognising critical thresholds in modifiable ecological pressures may enhance cost-effectiveness by determining optimal levels of intervention and identifying areas where impacts are unlikely. Limiting population antibiotic use to below critical levels may provide a powerful means to balance immediate clinical need with avoidance of resistance and sustainability of use. Further applications of our approach in other populations and clinical contexts is required to elucidate factors modifying thresholds for association with ecological variables, and to adapt antibiotic stewardship or infection control policies to local scenarios. These factors may include: age and comorbidities in the clinical population; baseline rates of MRSA; existing strain distributions; importation pressures; and interactions with other populations. Previous investigations have demonstrated complex within-host strain dynamics. Multilevel analyses could quantify the relative contribution of individual and population level exposures to acquisition or infection with specific strains. The relative weakness of existing hospital-based infection control measures in controlling CC5/other strains seen in this study suggests a pressing need for strategies to control burdens from clonal complexes arising in the community.

In conclusion, this study found evidence that changes in infection control and population antibiotic use have contributed to MRSA strain dynamics in Scotland over the past 16 years. Declines in overall clinical burdens from MRSA were convergent with intensified hospital infection control and antibiotic stewardship strategies removing selective pressures favouring hospital epidemic strains. Future efforts to control MRSA, and in particular evolving community strains, should consider thresholds for effects and strain-specific impacts.

Author affiliations
1Department of Paediatrics, Royal Aberdeen Children’s Hospital, Aberdeen, UK
2Medicine Preventive-Infection Control Team, Hospital Vega Baja, Orihuela-Alicante, Spain
3Centro Universitario de la Defensa (CUD) de San Javier, Murcia, Murcia, Spain
4Pharmacy Department, Aberdeen Royal Infirmary, Aberdeen, UK
5Medical Microbiology Department, Aberdeen Royal Infirmary, Aberdeen, UK
6Scottish MRSA Reference Laboratory, Glasgow, UK

Acknowledgements The authors wish to thank the Scottish MRSA Reference Laboratory, and health intelligence, medical microbiology and pharmacy departments of NHS Grampian, for their help in obtaining data.

Contributors TL, IMG, J-ML-L and CN designed the study, strain-typing was coordinated by GE, data-collection was by TL, GFSE, GM and RS-S, and analysis by TL, J-ML-L and CN. All authors reviewed and approved the final manuscript.

Funding This study was part of the TSARINAS (Time Series Analysis of Resistance, Infection control, and Antibiotic Stewardship) project, supported by grants from the NHS Grampian Clinical Microbiology Endowment Fund. No external funding was attached to this project.

Competing interests IMG consults and lectures for various pharmaceutical and diagnostic companies specialising in control of MRSA.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Original data are available upon request from the corresponding author.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES
1. Wertheim HFJ, Melles DC, Vos MC, et al. The role of nasal carriage in Staphylococcus aureus infections. *Lancet Infect Dis* 2005;5:751–62.
2. Jevons MP, Coo AW, Parker KT. Methicillin resistance in *staphylococcus*. *Lancet* 1963;1:904–7.
3. WHO. Antimicrobial resistance: Global Report on Surveillance 2014. Geneva, Switzerland. World Health Organisation, 2014. http://apps.who.int/iris/bitstream/10665/112642/1/9789241564747-eng.pdf?ua=1 (accessed 3 Sep 2014).
4. Hartman B, Tomasz A. Altered penicillin-binding proteins in methicillin-resistant strains of *Staphylococcus aureus*. *Antimicrob Agents Chemother* 1981;19:726–35.
5. Derensinski S. Methicillin-resistant staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. *Clin Infect Dis* 2005;40:562–73.
6. Noto MJ, Kreiswirth BN, Monk AB, et al. Gene acquisition at the insertion site for SCCmec, the genomic island conferring methicillin resistance in *Staphylococcus aureus*. *J Bacteriol* 2008;190:1276–83.
7. Otter JA, French GL. Molecular epidemiology of community-associated meticillin-resistant *Staphylococcus aureus* in Europe. *Lancet Infect Dis* 2010;10:227–36.
8. Popovich K, Hota B, Rice T, et al. Phenotypic prediction rule for community-associated meticillin-resistant *Staphylococcus aureus*. *J Clin Microbiol* 2007;45:2293–5.
9. Kouyos R, Klein E, Grenfell B. Hospital-community interactions foster coexistence between meticillin-resistant strains of *Staphylococcus aureus*. *PLoS Pathog* 2013;9:e1003134.
10. Kardas-Sloma L, Boèlle PY, Opatowski L, et al. Impact of antibiotic exposure patterns on selection of community-associated meticillin-resistant *Staphylococcus aureus* in hospital settings. *Antimicrob Agents Chemother* 2011;55:4888–95.
11. Kardas-Sloma L, Boelle PY, Opatowski L, et al. Antibiotic reduction campaigns do not necessarily decrease bacterial resistance: the example of meticillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2013;57:4410–16.
12. Stone SP, Fuller C, Savage J, et al. Evaluation of the national Cleanyourhands campaign to reduce *Staphylococcus aureus* bacteraemia and *Clostridium difficile* infection in hospitals in England and Wales by improved hand hygiene: four year, prospective, ecological, interrupted time series study. *BMJ* 2012;344:e3005.
13. Nathwani D, Sneddon J, Malcolm W, et al. Scottish Antimicrobial Prescribing Group (SAPG): development and impact of the Scottish...
National Antimicrobial Stewardship Programme. Int J Antimicrob Agents 2011;38:16–26.

14. Dixon J, Duncan CJ. Importance of antimicrobial stewardship to the English National Health Service. Infect Drug Resist 2014;7:145–52.

15. Thouvenot M, Laing NA, Hocevar D. Relationship between molecular epidemiology and antibiotic susceptibility of methicillin-resistant Staphylococcus aureus (MRSA) in a French teaching hospital. J Med Microbiol 2003;52:801–6.

16. Wylie D, Paul J, Crock D. Waves of trouble: MRSA strain dynamics and assessment of the impact of infection control. J Antimicrob Chemother 2011;66:2685–8.

17. Wylie DH, Walker AS, Miller R, et al. Decline of meticillin-resistant Staphylococcus aureus in Oxfordshire hospitals is strain-specific and preceded infection-control intensification. BMJ Open 2011;1:e000160.

18. McDermid PR, Tidton KE, Edwards GF. Molecular tracing of the emergence, adaptation, and transmission of hospital-associated methicillin-resistant Staphylococcus aureus. Proc Natl Acad Sci USA 2012;109:9107–12.

19. Donnio PY, Penney L, Gautier-Lerestif AL, et al. Changes in staphylococcal coagulase type and antibiotic resistance profile in methicillin-resistant Staphylococcus aureus isolates from a French hospital over an 11 year period. J Antimicrob Chemother 2004;53:808–13.

20. Colman SM, Reidcson TM, Udekwu KI, et al. Fitness cost: a bacteriological explanation for the demise of the first international methicillin-resistant Staphylococcus aureus epidemic. J Antimicrob Chemother 2012;67:1325–32.

21. Horváth A, Dobay O, Kardos S, et al. Varying fitness cost associated with resistance to fluoroquinolones governs clonal dynamic of methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 2012;31:2029–36.

22. Knight GM, Budd EL, Whitney L, et al. Shift in dominant hospital-associated methicillin-resistant Staphylococcus aureus (MRSA) clones over time. J Antimicrob Chemother 2012;67:2514–22.

23. Holden MTG, Hsu LY, Kurt K, et al. A genomic portrait of the emergence, evolution, and global spread of a methicillin-resistant Staphylococcus aureus pandemic. Genome Res 2013;23:653–64.

24. López-Lozano JM, Monnet DL, López-Lozano JM, et al. Temporal effects on antibiotic resistance and its dynamic relationship to antimicrobial use: a time series analysis. Int J Antimicrob Agents 2000;14:21–31.

25. Lawes T, Edwards B, López-Lozano JM, et al. Trends in Staphylococcus aureus bacteraemia and impacts of infection control practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus infection in England 2004–2010: retrospective cohort study and time-series intervention analysis. BMJ Open 2012;2:e000797.

26. Aldeyab MA, Monnet DL, López-Lozano JM, et al. Modelling the impact of antibiotic use and infection control practices on the incidence of MRSA. J Hosp Infect 2012;82:164–9.

27. MacKenzie FM, Lopez-Lozano JM, Sleekove C, et al. Temporal effects of infection control practices and the use of antibiotics on the incidence of MRSA. J Hosp Infect 2012;82:9–13.

28. Levy SB. Balancing the drug-resistance equation. Trends Microbiol 1994;2:341–2.

29. Austin DJ, Kristinsson KG, Anderson RM. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci USA 2011;108:19990–5.

30. Stone SP, Cooper BS, Kibbler CC, et al. The ORION statement: guidelines for transparent reporting of outbreak reports and intervention studies of nosocomial infection. J Antimicrob Chemother 2007;59:902–9.

31. WHO Collaborating Centre for Drug Statistics Methodology. ATC classification index with DDDs, 2013. http://www.whocc.no/atc_ddi_publications/atc_ddi_index/(accessed 3 Sep 2014).

32. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268–81.

33. Clements A, Halton K, Graves N, et al. Overcrowding and understaffing in modern health care systems: key determinants in meticillin-resistant Staphylococcus aureus transmission. Lancet Infect Dis 2008;8:427–34.

34. Reilly JS, Stewart S, Christie P, et al. Universal screening for meticillin-resistant Staphylococcus aureus: interim results from the Manchester study. J Hosp Infect 2010;74:35–41.

35. Dancer SJ. How do we assess hospital cleaning? A proposal for microbiological standards for surface hygiene in hospitals. J Hosp Infect 2004;56:10–15.

36. McVicker G, Prajsnar TK, Williams A, et al. Clonal expansion during Staphylococcus aureus infection dynamics reveals the effect of antibiotic intervention. PLoS Pathog 2014;10:e1003959.

37. Pressley J, D’Agata EMC, Webb GB. The effect of co-colonization with community-acquired and hospital-acquired methicillin-resistant Staphylococcus aureus strains on competitive exclusion. J Theor Biol 2010;264:645–50.

38. Beggs CB, Shepherd SJ, Kerr KG. Increasing the frequency of hand washing by healthcare workers does not lead to commensurate reductions in staphylococcal infection in a hospital ward. BMC Infect Dis 2008;8:114.

39. Beggs CB, Shepherd SJ, Kerr KG. How does healthcare worker hand hygiene behaviour impact upon the transmission of MRSA between patients? An analysis using a Monte Carlo model. BMC Infect Dis 2009;9:64.

40. Scotland. J Antimicrob Agents 2012;40:323–31.

41. Lawes T, Edwards B, López-Lozano JM, et al. Time-series analysis of the impact of bed occupancy rates on the incidence of methicillin-resistant Staphylococcus aureus infection in overcrowded general wards. Infect Control Hosp Epidemiol 2008;29:496–502.

42. Harbarth S, Fankhauser C, Schrenzel J, et al. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 2008;299:1149–57.

43. Sangal V, Girvan EK, Jadhav S, et al. Impacts of a long-term programme of active surveillance and chlorhexidine baths on the clinical and molecular epidemiology of meticillin-resistant Staphylococcus aureus (MRSA) in an Intensive Care Unit in a South Indian Hospital. J Antimicrob Chemother 2011;55:1598–605.

44. Harbarth S, Fankhauser C, Schrenzel J, et al. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 2008;299:1149–57.

45. Sangal V, Girvan EK, Jadhav S, et al. Impacts of a long-term programme of active surveillance and chlorhexidine baths on the clinical and molecular epidemiology of meticillin-resistant Staphylococcus aureus (MRSA) in an Intensive Care Unit in a South Indian Hospital. J Antimicrob Chemother 2011;55:1598–605.

46. Harbarth S, Fankhauser C, Schrenzel J, et al. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 2008;299:1149–57.

47. Sangal V, Girvan EK, Jadhav S, et al. Impacts of a long-term programme of active surveillance and chlorhexidine baths on the clinical and molecular epidemiology of meticillin-resistant Staphylococcus aureus (MRSA) in an Intensive Care Unit in a South Indian Hospital. J Antimicrob Chemother 2011;55:1598–605.

48. Harbarth S, Fankhauser C, Schrenzel J, et al. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 2008;299:1149–57.

49. Sangal V, Girvan EK, Jadhav S, et al. Impacts of a long-term programme of active surveillance and chlorhexidine baths on the clinical and molecular epidemiology of meticillin-resistant Staphylococcus aureus (MRSA) in an Intensive Care Unit in a South Indian Hospital. J Antimicrob Chemother 2011;55:1598–605.